Climb Bio
CLYM
109 hedge funds and large institutions have $734M invested in Climb Bio in 2026 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 22 closing their positions.
232% more capital invested
Capital invested by funds: $221M → $734M (+$513M)
136% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 22
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
36% more funds holding
Funds holding: 80 → 109 (+29)
30.77% more ownership
Funds ownership: 67.6% → 98.37% (+31%)
3% less call options, than puts
Call options by funds: $338K | Put options by funds: $349K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$34.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.8M |
| 5 |
BlackRock
New York
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.8M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$6.87M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.3M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$4.69M |
| 5 |
Millennium Management
New York
|
-$3.8M |
CLYM Hedge Fund Activity: Q2 2026 in Review
109 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q2 2026, worth a combined $734M — up 232% from $221M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CLYM positions and 22 closed out — a net gain of 30 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $70.1M. The largest seller was MPM BioImpact, exiting entirely with an estimated $17.8M sold.
- 109 institutional investors held Climb Bio (CLYM) as of Q2 2026, up from 80 in Q1 2026.
- Funds reported $734M of Climb Bio stock for Q2 2026, up 232% quarter-over-quarter.
- 52 funds opened new Climb Bio positions in Q2 2026 and 22 closed out, a net change of +30 holders.
- The largest Climb Bio buyer in Q2 2026 was Fidelity Investments, an estimated $70.1M added.
- The largest Climb Bio seller in Q2 2026 was MPM BioImpact, an estimated $17.8M sold.
Based on aggregated 13F filings for Q2 2026.